BRIEF published on 10/22/2024 at 22:50, 2 years ago DBV's Viaskin Peanut Patch Secures Regulatory Progress in US and EU FDA Approval DBV Technologies Viaskin Peanut Regulatory Update EMA Guidance
PRESS RELEASE published on 10/22/2024 at 22:45, 2 years ago DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV Technologies announces positive regulatory updates for Viaskin Peanut Patch in the United States and Europe, aiming for Accelerated Approval for toddlers 1-3 years old Accelerated Approval Regulatory Updates DBV Technologies Viaskin Peanut Patch Toddlers
BRIEF published on 10/18/2024 at 22:35, 2 years ago DBV Technologies to Engage in ACAAI 2024 Congress DBV Technologies Allergy Treatment Peanut Allergy Viaskin Peanut Patch ACAAI 2024
PRESS RELEASE published on 10/18/2024 at 22:30, 2 years ago DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies to participate in ACAAI 2024 Congress, presenting on optimal peanut allergy treatment and sponsoring FIT Bowl. Viaskin Peanut patch for food allergies highlighted DBV Technologies Food Allergies Viaskin Peanut Patch ACAAI 2024 Congress Peanut Allergy Treatment
BRIEF published on 10/14/2024 at 22:35, 2 years ago DBV Technologies Share Capital Status as of September 30, 2024 Share Capital Voting Rights DBV Technologies Euronext Exchanges Listed Shares
BRIEF published on 09/23/2024 at 22:35, 2 years 1 month ago DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial Clinical Trial Phase 3 DBV Technologies Viaskin Peanut Peanut Allergy
PRESS RELEASE published on 09/23/2024 at 22:30, 2 years 1 month ago DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial DBV Technologies completes screening for VITESSE Phase 3 Clinical Trial evaluating Viaskin Peanut Patch in peanut allergic children ages 4-7. Topline results expected Q4 2025 Clinical Trial DBV Technologies Food Allergies VITESSE Phase 3 Viaskin Peanut Patch
BRIEF published on 09/04/2024 at 22:35, 2 years 1 month ago DBV Technologies to Participate in 26th Annual HC Wainwright Global Investment Conference DBV Technologies Viaskin Food Allergies HC Wainwright Lecture Epicutaneous Immunotherapy
PRESS RELEASE published on 09/04/2024 at 22:30, 2 years 1 month ago DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies to participate in H.C. Wainwright 26th Annual Global Investment Conference with CEO Daniel Tassé in New York City. Focus on food allergy treatment and immunotherapy Immunotherapy DBV Technologies Food Allergies H.C. Wainwright Conference VIASKIN Patch
BRIEF published on 08/02/2024 at 22:35, 2 years 2 months ago DBV Technologies: Information as of July 31, 2024 on the number of shares and voting rights Share Capital Voting Rights AMF DBV Technologies NYSE Euronext Paris
Published on 10/28/2026 at 12:30, 8 hours 29 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 8 hours 29 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 8 hours 29 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 8 hours 29 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 12:15, 8 hours 44 minutes ago BULGOLD Expands Strategic Exploration Position Around the Lutila Gold Project with Two New Exploration Licences
Published on 10/28/2026 at 20:36, 22 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 20:35, 24 minutes ago EQS-Adhoc: Vonovia specifies Guidance for 2026 and adjusts Guidance for Organic Rent Growth and Operating Free Cash Flow for 2026; Publication of initial 2027 Guidance and revision of 2028 Objectives
Published on 10/28/2026 at 20:18, 41 minutes ago Turkiye Garanti Bankasi A.S.: BRSA Consolidated Earnings Presentation dated 30 September 2026
Published on 10/28/2026 at 18:45, 2 hours 14 minutes ago Knorr-Bremse delivers another strong quarter
Published on 10/28/2026 at 17:45, 3 hours 14 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 3 hours 14 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
Published on 10/28/2026 at 17:45, 3 hours 14 minutes ago Groupe CRIT : Revenue over 9 months 2026 : €2.55 billion (+2.2% organic growth).
Published on 10/28/2026 at 17:45, 3 hours 14 minutes ago Infotel : Acceleration of growth in Q3 2026: €77.9m (+11.3%). Confirmation of growth and profitability targets for 2026 as a whole.
